<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03626701</url>
  </required_header>
  <id_info>
    <org_study_id>CTP006-2</org_study_id>
    <nct_id>NCT03626701</nct_id>
  </id_info>
  <brief_title>RES® Prepared With RECELL® Compared to Standard of Care Dressings of Partial-thickness Burns in Ages 1-16 Years</brief_title>
  <official_title>A Prospective Multicenter Randomized Controlled Clinical Study to Investigate the Safety and Effectiveness of RES® (Regenerative Epidermal Suspension) Prepared With the RECELL® Device Compared to Standard of Care Dressings for Treatment of Partial-thickness Burns in Infants, Children and Adolescents (Aged 1-16 Years)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avita Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biomedical Advanced Research and Development Authority</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Avita Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, parallel-arm, randomized (1:1) multicenter trial to demonstrate that RECELL&#xD;
      treatment of partial-thickness burn injuries, can safely and effectively increase the&#xD;
      incidence of Day 10 healing compared with a standardized wound dressing.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 3, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Blinded Evaluator/Observer - local burn specialist&#xD;
Independent Reviewer</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Index Burns with Day 10 healing</measure>
    <time_frame>Day 10</time_frame>
    <description>Day 10 healing will be evaluated by an observer blinded to treatment allocation with confirmation at Day 28</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Index Burn Healing Confirmation</measure>
    <time_frame>Day 28</time_frame>
    <description>The Day 28 visit confirms the original incidence of healing recorded at Day 10</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Day 21 healing of the Index Burn</measure>
    <time_frame>Day 21, confirmed on Day 28</time_frame>
    <description>Incidence of Day 21 healing of the Index Burn confirmed on Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent area of Index Burn requiring autografting</measure>
    <time_frame>Through Day 28</time_frame>
    <description>Percent area of Index Burn requiring autografting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of conventional autografting to achieve healing of the Index Burn</measure>
    <time_frame>Through Day 28</time_frame>
    <description>Incidence of conventional autografting to achieve healing of the Index Burn</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Absolute area (cm2) of Index Burn requiring autografting</measure>
    <time_frame>Through Day 28</time_frame>
    <description>Absolute area (cm2) of Index Burn requiring autografting</description>
  </other_outcome>
  <other_outcome>
    <measure>Index Burn pain scores at dressing changes using the Face, Legs, Activity, Cry, Consolability (FLACC) scale</measure>
    <time_frame>Up to Week 8</time_frame>
    <description>Index Burn pain scores at dressing changes assessed by the HCP</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject reported Index Burn pain scores at dressing changes.</measure>
    <time_frame>Up to Week 8</time_frame>
    <description>Subject reported Index Burn pain scores at dressing changes.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent epithelialization of the Index Burn per digital planimetry</measure>
    <time_frame>Up to Week 8</time_frame>
    <description>Percent epithelialization of the Index Burn per digital planimetry</description>
  </other_outcome>
  <other_outcome>
    <measure>Index Burn Patient and Observer Scar Assessment Scale (POSAS) scar ratings</measure>
    <time_frame>Weeks 16, 24, 36 and 52</time_frame>
    <description>Index Burn Patient and Observer Scar Assessment Scale (POSAS) scar ratings</description>
  </other_outcome>
  <other_outcome>
    <measure>BOQ Outcomes (raw scores and recovery curves for all domains), with baseline at Day 10</measure>
    <time_frame>Day 10 and 28, Weeks 16, 24, 36 and 52</time_frame>
    <description>Outcomes (raw scores and recovery curves) from the Burn Outcomes Questionnaire (BOQ) Outcomes.</description>
  </other_outcome>
  <other_outcome>
    <measure>Investigator treatment preference</measure>
    <time_frame>Week 52</time_frame>
    <description>Investigator treatment preference by asking preference of RECELL or Control treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Health economics / medical resource utilization</measure>
    <time_frame>Through Week 52</time_frame>
    <description>Health economics / medical resource utilization (determined using UB-04 CMS-1500 and/or similar hospital claim forms for billing purposes to collect cost associated with the initial hospital care and readmissions during follow-up as applicable).</description>
  </other_outcome>
  <other_outcome>
    <measure>Index Burn Itch Man Scale ratings</measure>
    <time_frame>Up to Week 8</time_frame>
    <description>Index Burn Itch Man Scale ratings</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Burns</condition>
  <arm_group>
    <arm_group_label>RECELL® Autologous Cell Harvesting Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RECELL + Telfa™ Clear and Xeroform™ dressings&#xD;
Conventional autografting (only when indicated)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mepilex® Ag Wound Dressing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mepilex® Ag Wound Dressing&#xD;
Conventional autografting (only when indicated)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RECELL® Autologous Cell Harvesting Device</intervention_name>
    <description>Application of RES prepared using the RECELL® Autologous Cell Harvesting Device along with Telfa™ Clear primary and Xeroform™ secondary wound dressings.</description>
    <arm_group_label>RECELL® Autologous Cell Harvesting Device</arm_group_label>
    <other_name>RES (Regenerative Epidermal Suspension)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Mepilex® Ag Wound Dressing</intervention_name>
    <description>Application of Mepilex® Ag Wound Dressing on partial-thickness burn injury</description>
    <arm_group_label>Mepilex® Ag Wound Dressing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional autografting (only when indicated)</intervention_name>
    <description>When indicated, conventional autografting in accordance with Investigator's standard practice</description>
    <arm_group_label>Mepilex® Ag Wound Dressing</arm_group_label>
    <arm_group_label>RECELL® Autologous Cell Harvesting Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients aged 1 through 16 years (inclusive) with a partial-thickness&#xD;
             thermal burn injury.&#xD;
&#xD;
          2. The patient has a thermal burn injury that is:&#xD;
&#xD;
               1. ≤ 30% TBSA (exclusive of superficial areas) and&#xD;
&#xD;
               2. ≤ 10% of the burn injury TBSA is a full-thickness burn.&#xD;
&#xD;
          3. The Index Burn must be a clean partial-thickness burn injury &gt; or = to 160 cm2 and&#xD;
             between 2-20% BSA (inclusive).&#xD;
&#xD;
          4. The Index Burn may not cover the face, hand, foot or the perineum/genitalia (Note: a&#xD;
             patient with wounds in these areas may be enrolled but the Index Burn Area may not&#xD;
             include these areas).&#xD;
&#xD;
          5. The patient and/or guardian agrees to comply with all compulsory study procedures and&#xD;
             visit schedule.&#xD;
&#xD;
          6. The patient and/or parent/guardian agrees to abstain from any other treatment for&#xD;
             closure of the Index Burn for the duration of the study, unless medically necessary.&#xD;
&#xD;
          7. The patient and/or parent/guardian agrees to abstain from enrollment in any other&#xD;
             interventional clinical trial for the duration of the study.&#xD;
&#xD;
          8. In the opinion of the investigator, the patient and/or parent/guardian must be able&#xD;
             to:&#xD;
&#xD;
               1. Understand the full nature and purpose of the study, including possible risks and&#xD;
                  adverse events,&#xD;
&#xD;
               2. Understand instruction, and&#xD;
&#xD;
               3. Provide voluntary informed written consent/assent as appropriate for study&#xD;
                  participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Not able to understand English or Spanish.&#xD;
&#xD;
          2. Burns caused by chemicals, electricity or radiation.&#xD;
&#xD;
          3. Patients presenting with ONLY 3rd degree / full-thickness wounds which require&#xD;
             immediate autografting.&#xD;
&#xD;
          4. Burn injury has had prior treatment for definitive closure.&#xD;
&#xD;
          5. Patients for whom use of sedation/general anesthesia is not medically appropriate.&#xD;
&#xD;
          6. Superficial / trivial burns or burns that in the investigator's opinion appear to be&#xD;
             healing sufficiently such that care under this protocol would be inappropriate.&#xD;
&#xD;
          7. Patient requires immediate or staged surgical procedures for closure of their&#xD;
             partial-thickness burns.&#xD;
&#xD;
          8. Conditions, e.g., previous burn injury to study area, poor nutritional status, poorly&#xD;
             controlled diabetes mellitus (HbA1c&gt;9%), that in the investigator's opinion may&#xD;
             compromise subject safety or trial objectives.&#xD;
&#xD;
          9. Current use of medications, e.g., immunosuppressive agents (excluding inhaled&#xD;
             corticosteroids), that in the investigator's opinion may compromise subject safety or&#xD;
             trial objectives.&#xD;
&#xD;
         10. Inhalation injury.&#xD;
&#xD;
         11. Active infection, cellulitis or need for immediate grafting at the planned treatment&#xD;
             areas.&#xD;
&#xD;
         12. Concerns for parent/guardian's ability to provide appropriate follow-up care.&#xD;
&#xD;
         13. Subjects with a known hypersensitivity to trypsin or compound sodium lactate for&#xD;
             irrigation solution.&#xD;
&#xD;
         14. Subjects with a known sensitivity to silver.&#xD;
&#xD;
         15. In post-pubescent girls, pregnant or breast-feeding (pregnancy test should be&#xD;
             performed in accordance with local institutional requirements).&#xD;
&#xD;
         16. Immediate life-threatening condition or life expectancy less than one year.&#xD;
&#xD;
         17. Previous randomization within this investigation.&#xD;
&#xD;
        Post-Randomization Inclusion Criteria (prior to treatment):&#xD;
&#xD;
          1. Patient randomized (and will be treated) within 72 hours from the time of the burn&#xD;
             injury.&#xD;
&#xD;
          2. Patient continues to meet all pre-randomization inclusion criteria.&#xD;
&#xD;
        Post-Randomization Exclusion Criteria (prior to treatment):&#xD;
&#xD;
        1. Incidental finding of any pre-randomization exclusion criteria.&#xD;
&#xD;
        Consented subjects who do not meet the post-randomization eligibility criteria and did not&#xD;
        receive study treatment will be followed through the Day 28 visit and then withdrawn from&#xD;
        the study. The criteria for which exclusion was based will be documented.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Arizona Burn Center / Valleywise Health</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center New Orleans</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7600</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Christopher's Hospital for Children</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evan Hayes Burn Center, Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Regional Burn Center at Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 20, 2018</study_first_submitted>
  <study_first_submitted_qc>August 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2018</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediatric</keyword>
  <keyword>Burns</keyword>
  <keyword>Partial-thickness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

